News & Events
BD Announces Record Fiscal Fourth Quarter Revenues
|
Franklin Lakes, NJ (November 7, 2001) - BD (Becton, Dickinson and Company) (NYSE:BDX) today reported record revenues of $988 million for the fourth quarter ended September 30, 2001. Revenues increased 7 percent over the same period a year ago. At constant foreign exchange rates, revenues increased 10 percent. For the full year, the Company reported revenues of $3.8 billion, a 4 percent increase over a year ago, or 7 percent at constant foreign exchange rates. Reported revenues and earnings for fiscal 2001 reflect the adoption of the Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 101 (SAB 101), "Revenue Recognition in Financial Statements." The adoption of SAB 101, which affects the timing of revenue recognition of certain transactions, reduced fourth quarter revenues by about $8 million, and had a negligible impact on full year revenues. Diluted earnings per share for the fourth quarter were 49 cents, and $1.63 for the full year before a 14 cent non-cash cumulative effect adjustment recorded as of the beginning of fiscal 2001, each of which reflect the adoption of SAB 101. On a pre-SAB 101 basis, diluted earnings per share would have been 50 cents for the quarter and $1.63 for the full year. Additional details describing SAB 101 and its impact on the Company's fiscal 2001 quarterly revenues, net income and diluted earnings per share, as well as the related cumulative effect adjustment, are provided in a Note to the Consolidated Income Statements included with this press release. Diluted earnings per share in last year's fourth quarter of 32 cents included special charges associated with a worldwide organizational restructuring and certain estimated litigation costs, gains on investments and a favorable tax effect from the conclusion of certain tax audits. Excluding these items, diluted earnings per share for the fourth quarter of fiscal 2000 would have been 39 cents. Comparative reported diluted earnings per share for fiscal 2000 would have been $1.49. "We continue to deliver revenue and earnings growth in line with the commitments we have made to our shareholders," said Edward J. Ludwig, president and chief executive officer. "For the fourth quarter, as well as the year, our performance reflects the success of our key revenue growth drivers: safety-engineered devices, prefillable drug delivery devices and BD Biosciences products. This revenue growth, along with continued control over costs, has resulted in a significant improvement in operating margin and a 12 percent increase in net income before the SAB 101 accounting change in fiscal 2001." BD Medical Systems In the BD Medical Systems segment, worldwide revenues of $537 million increased 7 percent for the quarter, or 10 percent at constant foreign exchange rates. U.S. sales of safety-engineered products were $78 million in the fourth quarter, an 18 percent increase over the third quarter, and an 89 percent increase over the prior year's fourth quarter. Sales of safety-engineered products for the full year totaled $253 million, representing an increase of 55 percent over the prior year. Sales of prefillable drug delivery devices, which grew by 17 percent in the fourth quarter and 10 percent for the full year, also contributed to the overall growth of this segment. Reported segment growth for the quarter and year also benefited from a favorable comparison with the prior year's fourth quarter, which reflected the impact of discontinuing U.S. medical surgical distributor incentives in that quarter. Revenue growth was offset in part by lower recorded sales of diabetes syringes versus the prior year's fourth quarter. This is primarily the result of the Company beginning to redirect promotional efforts toward sustaining its branded syringe sales at the retail level and developing the U.S. pen needle market, as was discussed in the third quarter press release. In addition, the adoption of SAB 101 decreased fourth quarter diabetes syringe revenues by approximately $5 million. BD Clinical Laboratory Solutions In the BD Clinical Laboratory Solutions segment, worldwide revenues of $295 million increased 10 percent in the fourth quarter, or 12 percent at constant foreign exchange rates. U.S. sales of safety-engineered products were $50 million in the fourth quarter, a 17 percent increase over the third quarter, and an 84 percent increase over the prior year's fourth quarter. Sales of safety-engineered products for the full year totaled $163 million, representing an increase of 59 percent over the prior year. Reported segment growth for the quarter also benefited from a favorable comparison with the prior year's fourth quarter, which reflected the impact of discontinuing U.S. distributor incentives in that quarter. Growth in the segment also reflects increased worldwide sales of its molecular diagnostic platform, BD ProbeTec™ ET. BD Biosciences Revenues for the BD Biosciences segment grew 3 percent to $155 million in the fourth quarter. At constant foreign exchange rates, revenues increased 5 percent. The adoption of SAB 101 reduced the segment’s reported fourth quarter revenues by $3 million. The Company believes that the events of September 11 adversely affected fourth quarter revenues by as much as $5 million due to disruptions to air shipments and research and business activities at several private and government sector customers. Revenue growth for the year was 8 percent, or 11 percent at constant foreign exchange rates. Geographic Revenues Fourth quarter revenues in the United States increased 15 percent to $545 million. Revenues outside the United States of $442 million were about 1 percent below the prior year, although at constant foreign exchange rates revenues advanced 5 percent. For the full year, revenues in the U.S. increased 8 percent to $2 billion. Revenues of $1.7 billion outside the U.S. were about 1 percent below last year on a reported basis, but grew by 7 percent at constant foreign exchange rates. Fiscal 2002 Outlook The Company expects fiscal 2002 diluted earnings per share growth of approximately 10 percent over comparable fiscal 2001 diluted earnings per share of $1.63. In addition, the Company will adopt Statement of Financial Accounting Standards (SFAS) No. 142, "Goodwill and Other Intangible Assets," which, among other things, eliminates the requirement to amortize goodwill. The adoption is expected to result in additional earnings per share of approximately 9 cents relating to the elimination of goodwill amortization. The Company announced it also is considering actions to increase operating efficiency. These actions could include a smaller scale restructuring of manufacturing facilities in the BD Medical Systems segment. In addition, the Company is considering the divestiture of some business units with combined revenues of less than $200 million. Assuming that all of these actions are substantially completed during fiscal 2002, the Company would still expect earnings per share growth of approximately 10 percent, excluding any gains or losses on sales of business units or special charges. BD is a leading global medical technology company that manufacturers and sells a broad range of supplies, devices and systems for use by healthcare professionals, medical research institutions, industry and the general public. This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding the Company's performance, including future revenues, products and income, or events or developments that the Company expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of the Company and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; uncertainties of litigation; the Company's ability to achieve sales and earnings forecasts, which are based on sales volume and product mix assumptions, to achieve its cost savings objectives, and to achieve anticipated synergies and other cost savings in connection with acquisitions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in the Company's ability to maintain favorable supplier arrangements and relationships; changes in interest or foreign currency exchange rates; delays in product introductions; and changes in healthcare or other governmental regulation, as well as other factors discussed in this press release and in the Company's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements.
BD's news releases can be found on its website www.bd.com or through Business Wire at www.businesswire.com. A conference call with analysts regarding this news release will be broadcast live on BD's website at 8:30 a.m. EST Thursday, November 8, 2001, and will be available for replay at www.bd.com through November 15, 2001.
Contact:
BECTON, DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)
Three Months Ended September 30,
2001 2000 % Change
----------------------------------------------------------------
REVENUES $ 987,525 $ 919,898 7.4
Cost of products sold 497,745 470,556 5.8
Selling and administrative 257,383 247,228 4.1
Research and development 51,505 52,662 (2.2)
Special charges - 57,514 NM
----------------------------------------------------------------
TOTAL OPERATING COSTS
AND EXPENSES 806,633 827,960 (2.6)
----------------------------------------------------------------
OPERATING INCOME 180,892 91,938 96.8
Interest expense, net (7,697) (13,877) (44.5)
Gains on investments, net - 11,288 NM
Other income, net 30 2,221 (98.6)
----------------------------------------------------------------
INCOME BEFORE
INCOME TAXES 173,225 91,570 89.2
Income tax provision 40,815 7,556 NM
----------------------------------------------------------------
NET INCOME $ 132,410 $ 84,014 57.6
----------------------------------------------------------------
EARNINGS PER SHARE
Basic $ 0.51 $ 0.33 54.5
Diluted $ 0.49 $ 0.32 53.1
----------------------------------------------------------------
AVERAGE SHARES OUTSTANDING
Basic 258,952 253,526
Diluted 270,376 263,848
----------------------------------------------------------------
NM - Not Meaningful
All 2001 amounts presented in the Consolidated Income Statements
and Supplemental Revenue Information reflect the adoption of
Securities and Exchange Commission Staff Accounting Bulletin No. 101
(SAB 101), "Revenue Recognition in Financial Statements." See Note to
Consolidated Income Statements which discusses the adoption of SAB
101.
BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)
Twelve Months Ended September 30,
2001 2000 % Change
----------------------------------------------------------------
REVENUES $3,754,302 $3,618,334 3.8
Cost of products sold 1,913,292 1,848,332 3.5
Selling and
administrative 983,296 973,902 1.0
Research and development 211,834 223,782 (5.3)
Special charges - 57,514 NM
----------------------------------------------------------------
TOTAL OPERATING COSTS
AND EXPENSES 3,108,422 3,103,530 0.2
----------------------------------------------------------------
OPERATING INCOME 645,880 514,804 25.5
Interest expense, net (55,414) (74,197) (25.3)
Gains on investments, net - 76,213 NM
Other (expense) income, net (13,716) 3,114 NM
----------------------------------------------------------------
INCOME BEFORE
INCOME TAXES 576,750 519,934 10.9
Income tax provision 138,348 127,037 8.9
----------------------------------------------------------------
INCOME BEFORE
CUMULATIVE EFFECT OF
CHANGE IN ACCOUNTING
PRINCIPLE, NET OF TAX 438,402 392,897 11.6
Cumulative effect, net of tax (36,750) - NM
----------------------------------------------------------------
NET INCOME $ 401,652 $ 392,897 NM
----------------------------------------------------------------
BASIC EARNINGS PER SHARE
Before Cumulative Effect $ 1.69 $ 1.54 9.7
Cumulative Effect (0.14) - NM
----------------------------------------------------------------
Basic Earnings Per Share $ 1.55 $ 1.54 NM
----------------------------------------------------------------
DILUTED EARNINGS PER SHARE
Before Cumulative Effect $ 1.63 $ 1.49 9.4
Cumulative Effect (0.14) - NM
----------------------------------------------------------------
Diluted Earnings Per Share $ 1.49 $ 1.49 NM
----------------------------------------------------------------
AVERAGE SHARES OUTSTANDING
Basic 257,128 252,454
Diluted 268,833 263,239
----------------------------------------------------------------
NM - Not Meaningful
See Note to Consolidated Income Statements for discussion on the
adoption of SAB 101.
BECTON DICKINSON AND COMPANY
NOTE TO CONSOLIDATED INCOME STATEMENTS
SUMMARY OF ACCOUNTING CHANGE
Three Months and Twelve Months Ended September 30, 2001
As required by the SEC, BD adopted SAB No. 101 in the fourth
quarter of fiscal 2001, retroactive to October 1, 2000, and has
restated its first three quarters of 2001. SAB 101 provides the SEC's
views on the timing of revenue recognition for certain transactions
for which explicit guidance had not previously been available. The
adoption of SAB 101 is not expected to have a material effect on BD's
ongoing results.
Upon adoption of SAB 101, revenue from the sale of certain
instruments in the Biosciences segment are recognized upon
installation at the customer's site, rather than upon shipment. In
addition, the Company changed its method of accounting for revenue
related to those branded insulin syringe products that are sold under
incentive programs to distributors in the U.S. consumer trade channel.
The Company concluded that the more preferable method is to defer
revenue recognition until such product is sold by the distributor to
the end customer.
The adoption of SAB 101 had the effect of including in 2001
revenues, approximately $80.7 million of revenues and associated net
income that had been previously recognized in fiscal 2000. Similarly,
approximately $80.3 million of revenues which, prior to the adoption
of SAB 101, would have been included in fiscal 2001 were deferred to
2002. Consequently, the adoption of SAB 101 increased Biosciences
revenues for the year by $3.4 million and decreased Medical Systems'
revenues for the year by $3.1 million. As a result, the adoption of
SAB 101 did not have a significant impact on revenues, net income, or
earnings per share for the year. In accordance with SAB 101, BD
recorded a $0.14 per share cumulative effect adjustment in fiscal
2001. This adjustment offsets the net income associated with the
aforementioned $80.7 million of revenues that had previously been
recorded in fiscal 2000 and, therefore already reflected in the
Company's retained earnings.
All 2001 amounts presented in the Consolidated Income Statements
and Supplemental Revenue Information reflect the adoption of SAB 101.
The schedule that follows shows the impact of the adoption of SAB 101
by quarter for fiscal 2001. Also included in this exhibit are the
restated results for the first three quarters of fiscal 2001.
BECTON DICKINSON AND COMPANY
NOTE TO CONSOLIDATED INCOME STATEMENTS
FISCAL 2001 IMPACT OF SAB 101 ADOPTION ON REVENUES,
BY PRODUCT GROUP AND REGION
(Unaudited; Amounts in thousands)
Q1 Q2
---------------------------
CONSUMER HEALTH CARE
--------------------
United States $ 23,985 $ (6,431)
IMMUNOCYTOMETRY & REAGENTS
--------------------------
United States 3,660 (967)
International (582) (614)
----------------------------------------------------------------
TOTAL IMMUNOCYTOMETRY 3,078 (1,581)
----------------------------------------------------------------
NET INCREASE (DECREASE)
TO REVENUES $ 27,063 $ (8,012)
----------------------------------------------------------------
Q3 Q4(a)
---------------------------
CONSUMER HEALTH CARE
--------------------
United States $ (15,679) $ (4,933)
IMMUNOCYTOMETRY & REAGENTS
--------------------------
United States 122 (471)
International 4,655 (2,373)
----------------------------------------------------------------
TOTAL IMMUNOCYTOMETRY 4,777 (2,844)
----------------------------------------------------------------
NET INCREASE (DECREASE)
TO REVENUES $ (10,902) $ (7,777)
----------------------------------------------------------------
(a) The Consolidated Income Statement and Supplemental Revenue
Information for the fourth quarter reflect the adoption of SAB 101.
BECTON DICKINSON AND COMPANY
RESTATED FIRST QUARTER FISCAL 2001
(Unaudited; Amounts in thousands, except per-share data)
Three Months Ended December 31,
2000(a) 1999 % Change
----------------------------------------------------------------
REVENUES $ 870,320 $ 859,164 1.3
Cost of products sold 453,918 449,951 0.9
Selling and administrative 235,292 233,838 0.6
Research and development 52,727 53,743 (1.9)
----------------------------------------------------------------
TOTAL OPERATING COSTS
AND EXPENSES 741,937 737,532 0.6
----------------------------------------------------------------
OPERATING INCOME 128,383 121,632 5.6
Interest expense, net (18,564) (21,557) (13.9)
Other (expense) income, net (7,961) 1,674 NM
----------------------------------------------------------------
INCOME BEFORE
INCOME TAXES 101,858 101,749 0.1
Income tax provision 28,160 26,455 6.4
----------------------------------------------------------------
INCOME BEFORE
CUMULATIVE EFFECT OF
CHANGE IN ACCOUNTING
PRINCIPLE, NET OF TAX 73,698 75,294 (2.1)
Cumulative effect, net of tax (36,750) - NM
----------------------------------------------------------------
NET INCOME $ 36,948 $ 75,294 NM
----------------------------------------------------------------
BASIC EARNINGS PER SHARE
Before Cumulative Effect $ 0.29 $ 0.30 (3.3)
Cumulative Effect (0.14) - NM
----------------------------------------------------------------
Basic Earnings Per Share $ 0.15 $ 0.30 NM
----------------------------------------------------------------
DILUTED EARNINGS PER SHARE
Before Cumulative Effect $ 0.28 $ 0.29 (3.4)
Cumulative Effect (0.14) - NM
----------------------------------------------------------------
Diluted Earnings Per Share $ 0.14 $ 0.29 NM
----------------------------------------------------------------
AVERAGE SHARES OUTSTANDING
Basic 254,465 251,328
Diluted 266,237 262,593
----------------------------------------------------------------
NM - Not Meaningful
(a) All 2001 amounts presented reflect the adoption of SAB 101.
BECTON DICKINSON AND COMPANY
RESTATED SECOND QUARTER FISCAL 2001
(Unaudited; Amounts in thousands, except per-share data)
Three Months Ended March 31, 2001
2001(a) 2000 % Change
----------------------------------------------------------------
REVENUES $ 953,167 $ 925,132 3.0
Cost of products sold 486,738 473,987 2.7
Selling and administrative 241,912 244,063 (0.9)
Research and development 54,497 57,175 (4.7)
----------------------------------------------------------------
TOTAL OPERATING COSTS
AND EXPENSES 783,147 775,225 1.0
----------------------------------------------------------------
OPERATING INCOME 170,020 149,907 13.4
Interest expense, net (15,998) (21,199) (24.5)
Other (expense) income, net (5,418) 36,399 NM
----------------------------------------------------------------
INCOME BEFORE
INCOME TAXES 148,604 165,107 (10.0)
Income tax provision 34,439 45,936 (25.0)
----------------------------------------------------------------
NET INCOME $ 114,165 $ 119,171 (4.2)
----------------------------------------------------------------
EARNINGS PER SHARE
Basic $ 0.44 $ 0.47 (6.4)
Diluted $ 0.42 $ 0.45 (6.7)
----------------------------------------------------------------
AVERAGE SHARES OUTSTANDING
Basic 257,021 252,055
Diluted 269,172 263,376
----------------------------------------------------------------
NM - Not Meaningful
(a) All 2001 amounts presented reflect the adoption of SAB 101.
BECTON DICKINSON AND COMPANY
RESTATED THIRD QUARTER FISCAL 2001
(Unaudited; Amounts in thousands, except per-share data)
Three Months Ended June 30,
2001 (a) 2000 % Change
----------------------------------------------------------------
REVENUES $ 943,290 $ 914,140 3.2
Cost of products sold 474,891 453,838 4.6
Selling and administrative 248,709 248,773 -
Research and development 53,105 60,202 (11.8)
----------------------------------------------------------------
TOTAL OPERATING COSTS
AND EXPENSES 776,705 762,813 1.8
----------------------------------------------------------------
OPERATING INCOME 166,585 151,327 10.1
Interest expense, net (13,155) (17,564) (25.1)
Gains on investments, net - 31,766 NM
Other expense, net (367) (4,021) (90.9)
----------------------------------------------------------------
INCOME BEFORE
INCOME TAXES 153,063 161,508 (5.2)
Income tax provision 34,934 47,090 (25.8)
----------------------------------------------------------------
NET INCOME $ 118,129 $ 114,418 3.2
----------------------------------------------------------------
EARNINGS PER SHARE
Basic $ 0.46 $ 0.45 2.2
Diluted $ 0.44 $ 0.43 2.3
----------------------------------------------------------------
AVERAGE SHARES OUTSTANDING
Basic 258,086 252,904
Diluted 269,653 263,659
----------------------------------------------------------------
NM - Not Meaningful
(a) All 2001 amounts presented reflect the adoption of SAB 101.
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)
Three Months Ended September 30,
2001 2000 % Change
-----------------------------------
MEDICAL SYSTEMS
--------------
United States $ 281,652 $ 239,323 17.7
International 255,643 262,599 (2.6)
----------------------------------------------------------------
TOTAL $ 537,295 $ 501,922 7.0
----------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
United States $ 175,719 $ 149,517 17.5
International 119,306 118,423 0.7
----------------------------------------------------------------
TOTAL $ 295,025 $ 267,940 10.1
----------------------------------------------------------------
BIOSCIENCES
-----------
United States $ 87,878 $ 85,116 3.2
International 67,327 64,920 3.7
----------------------------------------------------------------
TOTAL $ 155,205 $ 150,036 3.4
----------------------------------------------------------------
TOTAL REVENUES
--------------
United States $ 545,249 $ 473,956 15.0
International 442,276 445,942 (0.8)
----------------------------------------------------------------
TOTAL $ 987,525 $ 919,898 7.4
----------------------------------------------------------------
Twelve Months Ended September 30,
2001 2000 % Change
----------------------------------
MEDICAL SYSTEMS
---------------
United States $1,007,601 $ 927,355 8.7
International 999,939 1,038,684 (3.7)
----------------------------------------------------------------
TOTAL $2,007,540 $1,966,039 2.1
----------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
United States $ 679,880 $ 623,490 9.0
International 474,872 478,862 (0.8)
----------------------------------------------------------------
TOTAL $1,154,752 $1,102,352 4.8
----------------------------------------------------------------
BIOSCIENCES
-----------
United States $ 329,042 $ 312,710 5.2
International 262,968 237,233 10.8
----------------------------------------------------------------
TOTAL $ 592,010 $ 549,943 7.6
----------------------------------------------------------------
TOTAL REVENUES
--------------
United States $2,016,523 $1,863,555 8.2
International 1,737,779 1,754,779 (1.0)
----------------------------------------------------------------
TOTAL $3,754,302 $3,618,334 3.8
----------------------------------------------------------------
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENT AND MAJOR PRODUCT GROUPS
Three Months Ended September 30,
(Unaudited; Amounts in thousands)
United States
-----------------------------------
2001 2000 % Change
-----------------------------------
MEDICAL SYSTEMS
---------------
Medical Surgical $ 178,590 $ 122,116 46.2
Consumer Health Care 77,349 96,239 (19.6)
Pharmaceutical Systems 19,142 14,716 30.1
Ophthalmic Systems 6,571 6,252 5.1
----------------------------------------------------------------
TOTAL $ 281,652 $ 239,323 17.7
----------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
Preanalytical Solutions $ 95,734 $ 71,262 34.3
Diagnostic Systems 79,985 78,255 2.2
----------------------------------------------------------------
TOTAL $ 175,719 $ 149,517 17.5
----------------------------------------------------------------
BIOSCIENCES
-----------
Immunocytometry & Reagents $ 65,019 $ 64,063 1.5
Discovery Labware 22,859 21,053 8.6
----------------------------------------------------------------
TOTAL $ 87,878 $ 85,116 3.2
----------------------------------------------------------------
TOTAL UNITED STATES $ 545,249 $ 473,956 15.0
----------------------------------------------------------------
International
-----------------------------------
2001 2000 % Change
-----------------------------------
MEDICAL SYSTEMS
---------------
Medical Surgical $ 146,435 $ 159,072 (7.9)
Consumer Health Care 44,804 46,667 (4.0)
Pharmaceutical Systems 58,300 51,223 13.8
Ophthalmic Systems 6,104 5,637 8.3
----------------------------------------------------------------
TOTAL $ 255,643 $ 262,599 (2.6)
----------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
Preanalytical Solutions $ 60,355 $ 59,264 1.8
Diagnostic Systems 58,951 59,159 (0.4)
----------------------------------------------------------------
TOTAL $ 119,306 $ 118,423 0.7
----------------------------------------------------------------
BIOSCIENCES
-----------
Immunocytometry & Reagents $ 50,988 $ 48,821 4.4
Discovery Labware 16,339 16,099 1.5
----------------------------------------------------------------
TOTAL $ 67,327 $ 64,920 3.7
----------------------------------------------------------------
TOTAL INTERNATIONAL $ 442,276 $ 445,942 (0.8)
----------------------------------------------------------------
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENT AND MAJOR PRODUCT GROUPS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)
Total
-----------------------------------
2001 2000 % Change
-----------------------------------
MEDICAL SYSTEMS
---------------
Medical Surgical $ 325,025 $ 281,188 15.6
Consumer Health Care 122,153 142,906 (14.5)
Pharmaceutical Systems 77,442 65,939 17.4
Ophthalmic Systems 12,675 11,889 6.6
----------------------------------------------------------------
TOTAL $ 537,295 $ 501,922 7.0
----------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
Preanalytical Solutions $ 156,089 $ 130,526 19.6
Diagnostic Systems 138,936 137,414 1.1
----------------------------------------------------------------
TOTAL $ 295,025 $ 267,940 10.1
----------------------------------------------------------------
BIOSCIENCES
-----------
Immunocytometry & Reagents $ 116,007 $ 112,884 2.8
Discovery Labware 39,198 37,152 5.5
----------------------------------------------------------------
TOTAL $ 155,205 $ 150,036 3.4
----------------------------------------------------------------
TOTAL REVENUES $ 987,525 $ 919,898 7.4
----------------------------------------------------------------
FX Neutral % Growth
-------------------------------
International Total
--------------- ---------------
MEDICAL SYSTEMS
---------------
Medical Surgical (1.2) 19.4
Consumer Health Care 2.0 (12.6)
Pharmaceutical Systems 20.1 22.3
Ophthalmic Systems 12.8 8.7
----------------------------------------------------------------
TOTAL 3.8 10.4
----------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
Preanalytical Solutions 6.5 21.7
Diagnostic Systems 4.8 3.3
----------------------------------------------------------------
TOTAL 5.7 12.3
----------------------------------------------------------------
BIOSCIENCES
-----------
Immunocytometry & Reagents 8.5 4.5
Discovery Labware 7.0 7.9
----------------------------------------------------------------
TOTAL 8.1 5.4
----------------------------------------------------------------
TOTAL 4.9 10.1
----------------------------------------------------------------
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENT AND MAJOR PRODUCT GROUPS
Twelve Months Ended September 30,
(Unaudited; Amounts in thousands)
United States
-----------------------------------
2001 2000 % Change
-----------------------------------
MEDICAL SYSTEMS
---------------
Medical Surgical $ 630,666 $ 544,532 15.8
Consumer Health Care 291,371 307,082 (5.1)
Pharmaceutical Systems 57,606 48,140 19.7
Ophthalmic Systems 27,958 27,601 1.3
----------------------------------------------------------------
TOTAL $1,007,601 $ 927,355 8.7
----------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
Preanalytical Solutions $ 345,699 $ 291,801 18.5
Diagnostic Systems 334,181 331,689 0.8
----------------------------------------------------------------
TOTAL $ 679,880 $ 623,490 9.0
----------------------------------------------------------------
BIOSCIENCES
-----------
Immunocytometry & Reagents $ 239,214 $ 231,793 3.2
Discovery Labware 89,828 80,917 11.0
----------------------------------------------------------------
TOTAL $ 329,042 $ 312,710 5.2
----------------------------------------------------------------
TOTAL UNITED STATES $2,016,523 $1,863,555 8.2
----------------------------------------------------------------
International
-----------------------------------
2001 2000 % Change
-----------------------------------
MEDICAL SYSTEMS
---------------
Medical Surgical $ 569,190 $ 612,043 (7.0)
Consumer Health Care 186,093 198,170 (6.1)
Pharmaceutical Systems 221,485 206,681 7.2
Ophthalmic Systems 23,171 21,790 6.3
----------------------------------------------------------------
TOTAL $ 999,939 $1,038,684 (3.7)
----------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
Preanalytical Solutions $ 239,634 $ 242,991 (1.4)
Diagnostic Systems 235,238 235,871 (0.3)
----------------------------------------------------------------
TOTAL $ 474,872 $ 478,862 (0.8)
----------------------------------------------------------------
BIOSCIENCES
-----------
Immunocytometry & Reagents $ 200,963 $ 174,906 14.9
Discovery Labware 62,005 62,327 (0.5)
----------------------------------------------------------------
TOTAL $ 262,968 $ 237,233 10.8
----------------------------------------------------------------
TOTAL INTERNATIONAL $1,737,779 $1,754,779 (1.0)
----------------------------------------------------------------
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENT AND MAJOR PRODUCT GROUPS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)
Total
-----------------------------------
2001 2000 % Change
-----------------------------------
MEDICAL SYSTEMS
---------------
Medical Surgical $1,199,856 $1,156,575 3.7
Consumer Health Care 477,464 505,252 (5.5)
Pharmaceutical Systems 279,091 254,821 9.5
Ophthalmic Systems 51,129 49,391 3.5
----------------------------------------------------------------
TOTAL $2,007,540 $1,966,039 2.1
----------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
Preanalytical Solutions $ 585,333 $ 534,792 9.5
Diagnostic Systems 569,419 567,560 0.3
----------------------------------------------------------------
TOTAL $1,154,752 $1,102,352 4.8
----------------------------------------------------------------
BIOSCIENCES
-----------
Immunocytometry & Reagents $ 440,177 $ 406,699 8.2
Discovery Labware 151,833 143,244 6.0
----------------------------------------------------------------
TOTAL $ 592,010 $ 549,943 7.6
----------------------------------------------------------------
TOTAL REVENUES $3,754,302 $3,618,334 3.8
----------------------------------------------------------------
FX Neutral % Growth
-------------------------------
International Total
--------------- ---------------
MEDICAL SYSTEMS
---------------
Medical Surgical - 7.5
Consumer Health Care 1.4 (2.6)
Pharmaceutical Systems 17.0 17.5
Ophthalmic Systems 13.9 6.8
----------------------------------------------------------------
TOTAL 3.9 6.2
----------------------------------------------------------------
CLINICAL LABORATORY SOLUTIONS
-----------------------------
Preanalytical Solutions 5.9 12.8
Diagnostic Systems 6.5 3.1
----------------------------------------------------------------
TOTAL 6.2 7.8
----------------------------------------------------------------
BIOSCIENCES
-----------
Immunocytometry & Reagents 23.3 11.8
Discovery Labware 6.5 9.1
----------------------------------------------------------------
TOTAL 18.9 11.1
----------------------------------------------------------------
TOTAL 6.6 7.4
----------------------------------------------------------------
|